Understanding the Clinical Challenge Behind Pre-Eclampsia Detection
Pre-eclampsia is a multisystem disorder that can occur after 20 weeks of gestation and remains a major cause of maternal and fetal/neonatal morbidity and mortality globally. One of the central difficulties in clinical practice is that early detection is challenging: elevated soluble fms-like tyrosine kinase-1 (sFlt-1) and decreased placental growth factor (PlGF) predict subsequent pre-eclampsia, yet biomarker levels vary by gestational age and pregnancy type. This variability means that clinicians evaluating suspected pre-eclampsia need tools that go beyond a single static threshold and instead account for the clinical context of each pregnancy.
Poclight, through its Pregnancy Care product line, positions itself as a supplier of point-of-care maternal-fetal diagnostic tools for pre-eclampsia risk assessment, combining biomarker interpretation with a portable dry micro analyzer. The company's approach centers on angiogenic biomarker testing—the quantitative measurement of sFlt-1 and PlGF and the calculation of the sFlt-1/PlGF ratio—to support, rather than replace, comprehensive clinical assessment.
How the sFlt-1/PlGF Ratio Supports Clinical Interpretation
Poclight's PlGF and sFlt-1 assays are intended for quantitative determination in human serum and plasma and can be used together to determine the sFlt-1/PlGF ratio. The company positions this ratio as an aid in the diagnosis of pre-eclampsia in conjunction with other diagnostic and clinical information, not as a standalone diagnostic answer.
The underlying biological logic is straightforward: as sFlt-1 rises and PlGF falls, the sFlt-1/PlGF ratio rises correspondingly, reflecting angiogenic imbalance associated with pre-eclampsia. This combined biomarker interpretation integrates the opposing changes of the two biomarkers into a single, more informative metric than either marker alone.
Several target scenario pain points shape the design of this solution. Clinical assessment may be difficult when pre-eclampsia is suspected but diagnostic features are incomplete or evolving. Angiogenic imbalance can provide additional biological information related to uteroplacental dysfunction. Because PlGF and sFlt-1 concentrations vary across gestation, biomarker interpretation must consider gestational age. Biomarker profiles also differ between singleton and multiple pregnancies, meaning thresholds established in singleton pregnancies should not automatically be extrapolated to twin pregnancies. Furthermore, clinical decision thresholds for PlGF and the sFlt-1/PlGF ratio may be assay- or platform-specific; published guidance such as NICE specifies different thresholds for different assay platforms.
Evidence-Informed Thresholds and Their Boundaries
Poclight's knowledge base references published external clinical evidence to frame how the ratio is typically interpreted, while being careful to distinguish these as external thresholds rather than Poclight-specific decision limits unless independently validated.
For example, published thresholds for one external assay platform describe a rule-out cut-off of ≤33 for gestational ages between 20+0 and 33+6 weeks, an intermediate range of >33 to <85, and a rule-in cut-off of ≥85. For pregnancies at ≥34+0 weeks to birth, the rule-out cut-off remains ≤33, the intermediate range shifts to >33 to <110, and the rule-in cut-off becomes ≥110. These gestational phase-specific thresholds answer a diagnostic question distinct from short-term prediction frameworks.
A separate, published short-term prediction framework—validated in singleton pregnancies with suspected pre-eclampsia between 24+0 and 36+6 weeks—uses a ratio of 38 to assess whether pre-eclampsia is unlikely within the next week (reported negative predictive value of 99.3%) or more likely within the next four weeks. Poclight's knowledge base explicitly notes that these two frameworks—gestational phase-specific diagnostic assessment and short-term prediction—answer different clinical questions and should not be combined into one continuous risk scale.

Separately, published PlGF-based testing frameworks use assay-specific thresholds for interpreting PlGF alone, further underscoring that thresholds are not universally interchangeable across assay platforms without independent validation.

Addressing Twin and Multiple Pregnancies
A notable aspect of Poclight's knowledge base is its explicit attention to twin and multiple pregnancies. Angiogenic biomarker profiles in twin pregnancies differ from those in singleton pregnancies, so singleton-derived thresholds should not automatically be applied to twins. While published research has proposed pregnancy-specific thresholds, there is not currently a universally established twin-specific sFlt-1/PlGF threshold suitable for transfer across all assays. This gestational age and twin-specific reference range awareness allows interpretation to support both singleton and twin pregnancies rather than assuming one-size-fits-all cut-offs.
The C5000 Dry Micro System: Enabling Point-of-Care Testing
Supporting this biomarker interpretation is Poclight's C5000 Dry Micro System, a compact dry micro analyzer built for rapid point-of-care testing. The platform addresses practical pain points in laboratory and clinical workflows: long turnaround times that delay clinical decisions, complex liquid paths and magnetic bead separation that raise maintenance and consumable costs, and limited portability that restricts use in point-of-care or space-constrained settings.
The C5000 delivers an initial sample result in 3 minutes with 7-channel operation, supporting rapid result availability. Both the sFlt-1 and PlGF assays are applicable to this analyzer, with a reported result time of approximately 5 minutes. Throughput reaches 80 tests/hour, supporting clinical workload demands, while the system's weight of ≤8.5 kg supports portable deployment. Accuracy is maintained with a coefficient of variation of <3%.
Operationally, the system is semi-automatic and portable, with a touch screen interface that simplifies workflow. It supports LIS/HIS transmission for real-time information sharing, allowing connectivity with hospital information systems. Importantly, the architecture eliminates magnetic beads, complex liquid paths, and requires wash-free separation—reducing consumables and maintenance burden compared to more complex liquid-path systems.
Reagents are available in lyophilized form for room temperature storage and transport, as well as in liquid form. The lyophilized beads support 2–30°C storage, reducing dependence on cold-chain logistics—a practical advantage for clinical laboratories, hospital obstetrics and gynecology departments, and point-of-care testing settings where cold-chain infrastructure may be limited.
A Clinically Grounded Approach to a Complex Problem
What distinguishes Poclight's positioning is not a claim of universal superiority but a disciplined, evidence-aware approach to a genuinely complex clinical problem. The company's knowledge base repeatedly emphasizes that gestational trend charts should be treated as biological trend illustrations rather than exact clinical reference ranges unless numerical reference intervals have been directly validated for the applicable assay. This qualification extends to published thresholds borrowed from other assay platforms, which are presented as external evidence rather than Poclight-specific performance claims unless independently validated.
For clinical laboratories, hospital obstetrics and gynecology departments, and point-of-care testing environments evaluating angiogenic biomarker testing solutions, Poclight's Pregnancy Care offering—paired with the C5000 Dry Micro System—presents a combination of quantitative sFlt-1 and PlGF measurement, ratio-based interpretation, gestational and pregnancy-type awareness, and a portable, rapid-turnaround testing platform. The emphasis throughout is on supporting clinical decision-making alongside other diagnostic and clinical information, reflecting the multifactorial nature of pre-eclampsia risk assessment itself.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

